ImmunityBio (IBRX) Earnings: Q3 2026 Results

The quarter ended September 30, 2026 and ImmunityBio published the results on November 9, 2026. Revenue and diluted EPS are shown against Q3 2025, the same quarter a year earlier, which takes seasonal swings out of the comparison.

• ImmunityBio's release gives no revenue or earnings outlook.
• Net loss per share was $0.17 basic and $0.18 diluted in Q3 2026. This page uses the diluted figure.

Source: ImmunityBio Q3 2026 results, November 9, 2026. Also in the Form 10-Q for the quarter ended September 30, 2026. Figures as reported; checked against the release on November 10, 2026.

How ImmunityBio splits revenue in its own release, under its own labels, for Q3 2026 against Q3 2025. Indented lines are parts of the line above them.

• ImmunityBio's Product revenue, net revenue was $48.7 million in Q3 2026, up 53% from $31.8 million in Q3 2025, 100% of total revenue.
• ImmunityBio's Other revenues revenue was $0.1 million in Q3 2026, down 63% from $0.3 million in Q3 2025, under 1% of total revenue.

Segment lines are the figures writers cite most often, because they show where the growth in a quarter came from. Companies redraw their segments from time to time and restate the prior year to match, so a year-ago figure here can differ from the one printed a year ago. When that has happened, the note above says so.

Revenue and diluted EPS for the last 5 quarters. Each date links to that quarter's release.

Total revenue and diluted net loss per share, each as first reported in that quarter's release. Swings in EPS mostly follow non-cash changes in the fair value of a related-party convertible note and warrant liabilities, which move with ImmunityBio's share price.

We do not hold a confirmed date for ImmunityBio's next report. Companies post the date on their investor relations site a few weeks ahead, usually with the time of the conference call.

Each quarter keeps its own page with the figures as reported, so a link to one stays pointed at the same numbers after the next report.

• Q3 2026 (this page), reported Nov 9, 2026

ImmunityBio has one product on the market, ANKTIVA, used with BCG to treat BCG-unresponsive non-muscle invasive bladder cancer. Net product revenue was $48.7 million in Q3 2026, up 53% from $31.8 million, and other revenues, mainly bioreactor and consumable sales and license royalties, were $0.1 million, for total revenue of $48.8 million. ImmunityBio says the $17.0 million rise came from higher sales of ANKTIVA. (ImmunityBio Q3 2026 release, Nov 9, 2026; ImmunityBio Form 10-Q, Q3 2026, Nov 9, 2026)

Almost all of the revenue is from the United States: $48.7 million, against $0.1 million from Europe, where ImmunityBio says the first patients were treated in November 2026. ANKTIVA is sold through a few customers. The top four accounted for about 98% of gross revenue in the quarter, at 53%, 19%, 19% and 7%. (ImmunityBio Form 10-Q, Q3 2026, Nov 9, 2026; ImmunityBio Q3 2026 release, Nov 9, 2026)

ImmunityBio recorded $10.2 million of gross-to-net adjustments as a reduction of revenue in Q3 2026, against $6.7 million a year earlier. For the first nine months of 2026, net product revenue was $143.6 million, up 92%, after $113.0 million for all of 2025. (ImmunityBio Form 10-Q, Q3 2026, Nov 9, 2026; ImmunityBio Q3 2026 release, Nov 9, 2026)

The label widened after the quarter. On October 14, 2026 the FDA approved ANKTIVA plus BCG for adults with BCG-unresponsive NMIBC with high-grade papillary-only tumors, and ImmunityBio said Cohort A of its QUILT-2.005 trial in BCG-naive patients met its primary endpoint, with a filing for that use planned in Q4 2026. It counts 35 countries where ANKTIVA is approved, after an approval in Israel. (ImmunityBio Q3 2026 release, Nov 9, 2026)

ImmunityBio's net loss attributable to common stockholders was $184.6 million in Q3 2026, or $0.18 per diluted share, against $67.3 million, or $0.07, a year earlier. The operating loss was $78.0 million, with research and development spending of $71.5 million and SG&A of $54.0 million. The larger share of the loss was $106.6 million of other expense, net. (ImmunityBio Q3 2026 release, Nov 9, 2026)

Most of that other expense is non-cash. Changes in the fair value of the related-party convertible note, warrant liabilities and other derivatives cost $77.9 million, mainly because ImmunityBio's share price rose during the quarter, after a $14.0 million gain a year earlier. Interest expense on the revenue interest liability with Oberland rose to $17.4 million from $12.3 million after additional funding in Q1 2026, and related-party interest expense was $14.6 million. (ImmunityBio Q3 2026 release, Nov 9, 2026; ImmunityBio Form 10-Q, Q3 2026, Nov 9, 2026)

ImmunityBio's adjusted net loss, which excludes the fair value changes and $8.7 million of stock-based compensation, was $97.9 million against $72.4 million. It does not report an adjusted figure per share. Diluted weighted-average shares rose to 1,060,937 thousand from 946,601 thousand, and 160,518 thousand shares underlying the convertible note, warrants, options and RSUs were excluded from diluted shares. (ImmunityBio Q3 2026 release, Nov 9, 2026; ImmunityBio Form 10-Q, Q3 2026, Nov 9, 2026)

Diluted EPS divides net income by the weighted average number of shares outstanding in the quarter, plus the shares that options and other equity awards could add. Buybacks shrink that count and lift EPS for the same profit; share issuance and stock awards enlarge it.

ImmunityBio does not publish a revenue or earnings outlook in its release. The milestones it names are regulatory: an sBLA for ANKTIVA plus BCG in BCG-naive NMIBC that it says is on track for submission in the fourth quarter of 2026, global filings for the papillary-only indication, and real-world evidence studies. (ImmunityBio Q3 2026 release, Nov 9, 2026)

A consensus figure is the average of the models published by the analysts who cover ImmunityBio, collected by a data provider and revised up to the day of the report. A quarter that lands above it says how expectations were set as much as how the business did, and the share price on the day also reflects the guidance and the lines no consensus covers.

The consensus figures on this page are Yahoo Finance's, as pulled on the date shown. Each comes with the number of analysts behind it; the smaller that number, the more one revised estimate can move the average.

The figures below are the ones ImmunityBio's own release and filings put weight on for Q3 2026, with the latest reported value for each.

What the quarter means for a holding is a separate question from what it reported. The case for and against owning IBRX is on is IBRX a buy or a sell?, what analysts expect next is on the IBRX forecast, and what the company does is on the ImmunityBio (IBRX) stock page.

Every number on this page can be traced to a document ImmunityBio published. Checking one takes a couple of minutes, and it is worth doing before you quote a figure anywhere.

• The results release is the document linked in the source line above. Companies publish it on their investor relations site at the moment results go out, and it carries the headline tables: revenue, operating income, net income and EPS for the quarter and the year-ago quarter.
• The same release is filed with the SEC as Exhibit 99.1 to a Form 8-K under Item 2.02, usually on the day of the report. The SEC copy does not change after the fact, which makes it the safer thing to link when you cite a number.
• The quarterly report (Form 10-Q) follows within a few weeks and carries the full financial statements, the segment note and management's discussion of what changed. The fourth quarter is covered by the annual report (Form 10-K) instead.
• Restated comparisons are flagged in the notes on this page. When a company redraws its segments or changes how it adjusts EPS, it restates the year-ago column, so the year-ago figure in a new release can differ from the one printed a year ago. This page always uses the comparison in the newer release, because that is the like-for-like one.

A walk-through of every line in a release, with what each one tells you, is in how to read an earnings report.